| Autor: |
Anouk H. Eijkelboom, Linda de Munck, Marie-Jeanne T. F. D. Vrancken Peeters, Mireille J. M. Broeders, Luc J. A. Strobbe, Monique E. M. M. Bos, Marjanka K. Schmidt, Cristina Guerrero Paez, Marjolein L. Smidt, Maud Bessems, Janneke Verloop, Sabine Linn, Marc B. I. Lobbes, Aafke H. Honkoop, Desirée H. J. G. van den Bongard, Pieter J. Westenend, Jelle Wesseling, C. Willemien Menke-van der Houven van Oordt, Vivianne C. G. Tjan-Heijnen, Sabine Siesling, the NABON COVID-19 Consortium and the COVID and Cancer-NL Consortium |
| Jazyk: |
angličtina |
| Rok vydání: |
2021 |
| Předmět: |
|
| Zdroj: |
Journal of Hematology & Oncology, Vol 14, Iss 1, Pp 1-12 (2021) |
| Druh dokumentu: |
article |
| ISSN: |
1756-8722 |
| DOI: |
10.1186/s13045-021-01073-7 |
| Popis: |
Abstract Background The onset of the COVID-19 pandemic forced the Dutch national screening program to a halt and increased the burden on health care services, necessitating the introduction of specific breast cancer treatment recommendations from week 12 of 2020. We aimed to investigate the impact of COVID-19 on the diagnosis, stage and initial treatment of breast cancer. Methods Women included in the Netherlands Cancer Registry and diagnosed during four periods in weeks 2–17 of 2020 were compared with reference data from 2018/2019 (averaged). Weekly incidence was calculated by age group and tumor stage. The number of women receiving initial treatment within 3 months of diagnosis was calculated by period, initial treatment, age, and stage. Initial treatment, stratified by tumor behavior (ductal carcinoma in situ [DCIS] or invasive), was analyzed by logistic regression and adjusted for age, socioeconomic status, stage, subtype, and region. Factors influencing time to treatment were analyzed by Cox regression. Results Incidence declined across all age groups and tumor stages (except stage IV) from 2018/2019 to 2020, particularly for DCIS and stage I disease (p |
| Databáze: |
Directory of Open Access Journals |
| Externí odkaz: |
|
